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Introduction
Monomethyl auristatin E and F (MMAE and MMAF, 1 and 2 in
Figure 1) are synthetic analogues of dolastatin 10, a highly cy-
totoxic pseudopeptide extracted from the sea hare Dolabella
auricularia. Similar to the original natural product, these ana-
logues exert potent cytotoxic activity by strongly inhibiting mi-
crotubule assembly and tubulin-dependent GTP hydrolysis, re-
sulting in cell-cycle arrest and apoptosis.[1]
Due to their extremely high cytotoxicity, dolastatin ana-
logues cannot be used as drugs themselves and have been ex-
ploited as optimal payloads for antibody–drug conjugates
(ADCs) and other tumor-targeting strategies.[2] ADCs have
emerged as powerful tools for limiting the main drawbacks of
anticancer drugs, such as severe side effects and the emer-
gence of multidrug resistance.[3] Indeed, among the four ADCs
approved and commercially available, brentuximab vedotin
(AdcetrisTM) bears MMAE linked to an anti-CD30 monoclonal
antibody via the protease-cleavable Val-Cit dipeptide linker.[4]
MMAF differs from MMAE in the presence of a charged C-ter-
minal phenylalanine residue, which limits its membrane per-
meability, attenuating off-target toxicity.[2a] Although MMAF
displays lower cytotoxicity than the more lipophilic MMAE,
both drugs have shown similar activity (IC50 values in the sub-
nanomolar range) when released intracellularly by ADCs.[2a,5]
Moreover, the different physicochemical properties of the two
payloads were found to have important implications in the rel-
ative mechanism of action in vivo: cell-permeable MMAE is
able to diffuse through neighboring cells, extending its toxic
activity to other cells in the tumor microenvironment (bystand-
er-killing effect), whereas MMAF is mostly retained inside the
This work reports the synthesis of a series of small-molecule–
drug conjugates containing the aVb3-integrin ligand cyclo[DKP-
RGD] or cyclo[DKP-isoDGR], a lysosomally cleavable Val-Ala (VA)
linker or an “uncleavable” version devoid of this sequence, and
monomethyl auristatin E (MMAE) or F (MMAF) as the cytotoxic
agent. The conjugates were obtained via a straightforward syn-
thetic scheme taking advantage of a copper-catalyzed azide–
alkyne cycloaddition as the key step. The conjugates were
tested for their binding affinity for the isolated avb3 receptor
and were shown to retain nanomolar IC50 values, in the same
range as those of the free ligands. The cytotoxic activity of the
conjugates was evaluated in cell viability assays with avb3 in-
tegrin overexpressing human glioblastoma (U87) and human
melanoma (M21) cells. The conjugates possess markedly lower
cytotoxic activity than the free drugs, which is consistent with
inefficient integrin-mediated internalization. In almost all cases
the conjugates featuring isoDGR as integrin ligand exhibited
higher potency than their RGD counterparts. In particular, the
cyclo[DKP-isoDGR]-VA-MMAE conjugate has low nanomolar IC50
values in cell viability assays with both cancer cell lines tested
(U87: 11.50:0.13 nm ; M21: 6.94:0.09 nm) and is therefore a
promising candidate for in vivo experiments.
Figure 1. Molecular structures of monomethyl auristatin-E (1) and mono-
methyl auristatin-F (2).
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target cancer cell due to its poor membrane permeability, re-
sulting in increased intracellular accumulation.[6]
In the last decades, low-molecular-weight ligands (e.g. , pep-
tides, peptidomimetics, aptamers, vitamins, and substrate ana-
logues) that can be easily accessed by chemical synthesis, have
been investigated as carriers for cytotoxic agents, aiming at
overcoming important limitations of ADCs, such as high manu-
facturing costs, unfavorable pharmacokinetics (low tissue diffu-
sion and low accumulation rate), and possible immunogenici-
ty.[7] Similar to ADCs, the so-called small-molecule–drug conju-
gates (SMDCs) feature three fundamental parts (i.e. , ligand, cy-
totoxic drug, and linker) and are generally designed to deliver
the payload in intracellular compartments of cancer cells (e.g. ,
lysosomes), although non-internalizing SMDCs have also been
developed.[8]
Among the suitable targets for drug delivery, the transmem-
brane avb3 integrin receptor is overexpressed on the cell sur-
face of various tumor types (such as melanoma, glioblastoma,
renal cell carcinoma, and tumors of lung, ovary, breast, pros-
tate, and colon),[9] where it is involved in various steps of
tumor growth. Since the discovery that endogenous ligands
bind integrin avb3 through the tripeptide sequences Arg-Gly-
Asp (RGD)[10] and isoAsp-Gly-Arg (isoDGR),[11] many peptides
and peptidomimetics containing these motifs have been de-
signed, leading to high-affinity avb3 integrin ligands.
[12]
Our research group entered this field by developing cyclic
RGD and isoDGR integrin ligands containing a bifunctional di-
ketopiperazine (DKP) scaffold.[13] Notably, the integrin ligands
cyclo[DKP-RGD] and cyclo[DKP-isoDGR] (3 and 4, Figure 2) dis-
played low-nanomolar IC50 values in competitive binding
assays against the purified aVb3 receptor as well as marked se-
lectivity toward the aVb3 receptor relative to aVb5.
[13d]
Later, compounds 3 and 4 were functionalized with a ben-
zylamine moiety (5 and 6, Figure 2) allowing their conjugation
to different bioactive molecules.[14–16] Conjugates of the func-
tionalized integrin ligands 5 and 6 with the antimitotic drug
paclitaxel (PTX) were synthesized featuring a self-immolative
spacer and the lysosomally cleavable Val-Ala (VA) linker.[15,16]
More recently, ligands 5 and 6 were bound to the RNA poly-
merase II inhibitor a-amanitin via a 6’-ether, giving cyclo[DKP-
RGD]-VA-a-amanitin and cyclo[DKP-isoDGR]-VA-a-amanitin con-
jugates.[17] Cell viability assays indicated a slightly increased cy-
totoxicity of the cyclo[DKP-isoDGR]-VA-a-amanitin conjugate
relative to the free drug.[17]
To further investigate the efficacy of our SMDCs, herein we
report the synthesis of novel conjugates bearing the avb3 in-
tegrin ligand 5 or 6 and MMAE or MMAF as payload (7–14,
Figure 3). We evaluated the binding affinity of conjugates 7–14
toward the isolated avb3 integrin receptor and their cytotoxic
activities on human glioblastoma (U87) and human melanoma
(M21) cell lines, which are known to overexpress the aVb3 in-
tegrin receptor.
Results and Discussion
Synthesis of conjugates 7–14
Conjugates 7–14 (Figure 3), including two cyclo[DKP-RGD]-
MMAE (7 and 9), two cyclo[DKP-isoDGR]-MMAE (8 and 10), two
cyclo[DKP-RGD]-MMAF (11 and 13), and two cyclo[DKP-
isoDGR]-MMAF (12 and 14), were synthesized as discussed
below. In these conjugates, the integrin ligands are bound to
MMAE and MMAF payloads via: 1) a p-aminobenzylcarbamate
(PABC) self-immolative spacer and a lysosomally cleavable VA
linker or an “uncleavable” version devoid of this sequence, 2) a
triazole linkage, and 3) a PEG-4 spacer. The synthesis of cy-
clo[DKP-RGD]-MMAE/MMAF (7, 9, 11 and 13) and cyclo[DKP-
isoDGR]-MMAE/MMAF (8, 10, 12 and 14) conjugates was per-
formed through the linear synthetic strategy shown in
Figure 2. A. ligand cyclo[DKP-RGD] (3) and its functionalized version (5) ;
B. ligand cyclo[DKP-isoDGR] (4) and its functionalized version (6).
Figure 3. MMAE/MMAF conjugates: cyclo[DKP-RGD]-VA-MMAE (7), cyclo[DKP-isoDGR]-VA-MMAE (8), cyclo[DKP-RGD]-Unc-MMAE (9), cyclo[DKP-isoDGR]-Unc-
MMAE (10), cyclo[DKP-RGD]-VA-MMAF (11), cyclo[DKP-isoDGR]-VA-MMAF (12), cyclo[DKP-RGD]-Unc-MMAF (13), cyclo[DKP-isoDGR]-Unc-MMAF (14).
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Scheme 1. The Fmoc-protected VA-p-aminobenzyl alcohol (15)
was synthesized according to a previously reported proce-
dure.[15] Upon Fmoc removal from 15, the resulting free amine
was treated with 4-pentynoic acid, leading to compound 16 in
high yield. The latter was then converted into the correspond-
ing 4-nitrophenyl carbonate (17). The secondary amine of
MMAE and MMAF was derivatized with the linker by treatment
with 4-nitrophenyl carbonate 17, leading to carbamates 18
and 19. The final conjugates 7–8 and 11–12 were obtained
through a copper-catalyzed azide–alkyne cycloaddition
(CuAAC)[18] between alkynes 18–19 and the azide-functional-




For the preparation of conjugates bearing an uncleavable
linker (9–10 and 13–14, Scheme 1B), 4-pentynoic acid was re-
acted with the secondary amine of MMAE and MMAF, affording
tertiary amides 22 and 23 in good yields. Then, the CuAAC
with functionalized ligands 20 and 21 afforded the uncleavable
conjugates 9–10 and 13–14. All final compounds were purified
by semipreparative HPLC and lyophilized before biological
assays.
aVb3 Integrin receptor competitive binding assays
Conjugates 7–14 were evaluated for their ability to inhibit bio-
tinylated vitronectin binding to the isolated aVb3 receptor. The
competitive binding assay was performed by incubating the
immobilized integrin receptor with solutions of the cyclo[DKP-
RGD]-MMAE/MMAF (7, 9, 11, and 13), cyclo[DKP-isoDGR]-
MMAE/MMAF (8, 10, 12 and 14) conjugates at different con-
centrations (10@12 to 10@5m) in the presence of biotinylated vi-
tronectin (1 mgmL@1) and measuring bound vitronectin. The
calculated half-maximal inhibitory concentrations (IC50) listed in
Table 1 demonstrate that conjugates 7–14 retain good binding
affinity for integrin avb3, with IC50 values in the nanomolar
range, similar to or only slightly worse than those of the free li-
gands 3 and 4.
Cell viability assays
The antiproliferative activity of compounds 7–14 was evaluat-
ed against avb3-integrin-overexpressing human glioblastoma
(U87) and human melanoma (M21) cells.[19,20] The cells were
treated for 72 hours with increasing doses of free MMAE (1),
MMAF (2) and MMAE/MMAF conjugates 7–14, and the cell via-
Scheme 1. Synthesis of conjugates 7–14 : a) 1) piperidine, DMF, RT, 2 h; 2) 4-pentynoic acid, HATU, HOAt, iPr2NEt, DMF, RT, overnight; b) 4-nitrophenyl chloro-
formate, pyridine, RT, THF, 2 h; c) MMAE, HOBt, iPr2NEt, RT, DMF/pyridine (4:1), 65 h; d) MMAF·HCl, HOBt, iPr2NEt, RT, DMF/pyridine (4:1), 65 h; e) (avb3-integrin
ligand)-PEG-4-N3, CuSO4·5H2O, NaAsc, DMF/H2O (1:1), 35 8C, overnight; f) 4-pentynoic acid, MMAE, HATU, HOAt, iPr2NEt, DMF, RT, overnight; g) 4-pentynoic
acid, MMAF·HCl, HATU, HOAt, iPr2NEt, DMF, RT, overnight. HATU=1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophos-
phate; HOAt=1-hydroxy-7-azabenzotriazole; HOBt=1-hydroxybenzotriazole; iPr2NEt=N,N-diisopropylethylamine; RT= room temperature; NaAsc= sodium
ascorbate.
Table 1. Inhibition of biotinylated vitronectin binding to the isolated
aVb3 receptor.












[a] IC50 values were calculated as the concentration of compound re-
quired for 50% inhibition of biotinylated vitronectin binding to the avb3
receptor, as estimated by GraphPad Prism software. All values are the
arithmetic mean:SD of duplicate determinations.
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bility was then evaluated by MTT assay. The calculated IC50
values are listed in Table 2.
Under these experimental conditions, MMAE (1) proved to
be much more potent than MMAF (2), confirming published
data.[1, 2a] In general, the antiproliferative activity of the integ-
rin-targeted conjugates was found to be lower than the parent
free drugs. In the case of the MMAE conjugates with uncleava-
ble linker (9 and 10), the loss of potency is greater than three
orders of magnitude (+5V103). When the linker is cleavable (7
and 8), the potency is still reduced, but to a lesser extent, with
the cyclo[DKP-isoDGR]-VA-MMAE conjugate 8 showing low
nanomolar IC50 values, only two orders of magnitude worse
than the free drug.
Antibody–MMAF conjugates display IC50 values in the sub-
nanomolar range because of assisted internalization. Moreover,
antibody–MMAF (and not MMAE) conjugates tolerate uncleav-
able linkers coupled to the drug N terminus.[2a,21] These effects
are clearly absent in Table 2, where the IC50 values of the integ-
rin ligand–MMAF conjugates are at best in the sub-micromolar
range. These results are consistent with the observation that
the cyclo[DKP-RGD] ligand accumulates on the cell membrane
of aVb3-integrin-expressing cancer cells, while it is poorly inter-
nalized by receptor-mediated endocytosis.[8e]
Finally, our data show that in almost all cases the com-
pounds featuring cyclo[DKP-isoDGR] as integrin ligand exhibit-
ed higher potency than their analogues equipped with cy-
clo[DKP-RGD]. This is evident in comparing cyclo[DKP-isoDGR]-
VA-MMAE (8) and cyclo[DKP-RGD]-VA-MMAE (7) both in U87
and M21 cancer cell lines (3.4- and 7.9-fold more potent, re-
spectively).
Conclusions
Conjugation of anticancer drugs to avb3 integrin ligands repre-
sents a promising approach in tumor-targeted chemotherapy.
In this work, we synthesized eight conjugates 7–14 bearing
the aVb3-integrin ligands cyclo[DKP-RGD] 3 or cyclo[DKP-
isoDGR] 4 and the potent tubulin polymerization inhibitor
MMAE (1) or MMAF (2), widely investigated as payloads in anti-
body–drug conjugates (ADCs). Conjugates 7, 8 and 11, 12 con-
tain the lysosomally cleavable VA linker, whereas conjugates 9,
10 and 13, 14 present an uncleavable linker. Conjugates 7–14
were found to inhibit biotinylated vitronectin binding to the
purified avb3 receptor at nanomolar concentrations, retaining
the excellent integrin binding affinity of the free ligands. In ad-
dition, conjugates 7–14 were evaluated in vitro for their activi-
ty against the avb3-overexpressing U87 and M21 cancer cell
lines. Overall, the cell viability data shown in Table 2 indicate
that the conjugates bearing both peptidomimetic ligands cy-
clo[DKP-RGD] and cyclo[DKP-isoDGR] possess lower anticancer
activity than the free drugs, which is consistent with inefficient
integrin-mediated internalization of the conjugates by the tar-
geted cancer cell.
However, the isoDGR-bearing conjugates display a systemati-
cally higher anticancer activity than their RGD counterparts,
suggesting the possibility that the cyclo[DKP-isoDGR] is able to
promote a more significant internalization with respect to the
cyclo[DKP-RGD] ligand; this will be explored in future experi-
ments. In particular, the cyclo[DKP-isoDGR]-VA-MMAE conjugate
(8) shows higher activity than cyclo[DKP-RGD]-VA-MMAE (7)
upon incubation with both U87 and M21 cancer cell lines (3.4-
and 7.9-fold, respectively). The low nanomolar IC50 values in
both cancer cell lines (U87: 11.50:0.13 nm ; M21: 6.94:
0.09 nm) suggest that the cyclo[DKP-isoDGR]-VA-MMAE conju-
gate (8) is a promising candidate for in vivo experiments,
which will be important to obtain evidence of conjugate accu-
mulation at the tumor site. Further studies will include the use
of extracellularly cleavable linkers to exploit the passive diffu-
sion properties of MMAE. Indeed, the latter is an emerging
strategy in the drug delivery field, supported by recent evi-
dence of promising anticancer activity by non-internalizing
ADCs[22] and SMDCs.[8e,23]
Experimental Section
MMAE and MMAF drugs are commercially available from Levena
Biopharma (USA) and Oskar Tropitzsch GmbH (Germany). Ligands
cyclo[DKP-RGD] (3) and cyclo[DKP-isoDGR] (4), their functionalized
analogues 5 and 6, Fmoc-Val-Ala-PABA (15) and azide-PEG-4-li-
gands 20 and 21 were prepared according to the cited literature.
The synthetic procedures for the preparation of compounds 7–14
are reported in the Supporting Information, along with the 1H NMR
and 13C NMR spectra, HPLC traces, and HRMS spectra. The inhibi-
tion assays of biotinylated vitronectin binding to the avb3 receptor
for compounds 7–14 are given in the Supporting Information. The
cell antiproliferative studies on U87 and M21 cell lines are also de-
scribed in the Supporting Information.
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